Clinical Trial Update: Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) [Phase 3]

View source ↗

Summary

A Phase 3 trial (CARES) comparing the cardiovascular safety of febuxostat versus allopurinol in gout patients with cardiovascular comorbidities completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Gout

Drugs mentioned

• Allopurinol (Allopurinol)
• FEBUXOSTAT (Febuxostat)

Snippet

Sponsor: Takeda | Conditions: Cardiovascular Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-06-14